| Literature DB >> 35054111 |
Keisuke Natsume1,2, Harutoshi Sakakima2, Kentaro Kawamura1, Akira Yoshida1,2, Shintaro Akihiro1, Hajime Yonezawa3, Koji Yoshimoto3, Megumi Shimodozono1.
Abstract
Glioblastoma multiforme (GBM) is the most common and aggressive brain tumor. To identify the factors influencing the improvement of the activities of daily living (ADL) in newly diagnosed patients with GBM, we investigated the characteristics and variable factors and overall survival. A total of 105 patients with GBM were retrospectively analyzed and categorized into the following three groups according to the quartile of change of their Barthel index score from admission to discharge: deterioration (n = 25), no remarkable change (n = 55), and good recovery (n = 25). A statistical difference was observed in the pre-operative, intra-operative, post-operative, and rehabilitation-related factors between the deterioration and good recovery groups. Multiple regression analysis identified the following significant factors that may influence the improvement of ADL after surgery: the improvement of motor paralysis after surgery, mild fatigue during radio and chemotherapy, and length up to early walking training onset. The median overall survival was significantly different between the deterioration (10.6 months) and good recovery groups (18.9 months, p = 0.025). Our findings identified several factors that may be associated with post-operative functional improvement in patients with GBM. The inpatient rehabilitation during radio and chemotherapy may be encouraged without severe adverse events and can promote functional outcomes, which may contribute to the overall survival of newly diagnosed patients with GBM.Entities:
Keywords: glioblastoma; motor paralysis; overall survival; performance status; rehabilitation
Year: 2022 PMID: 35054111 PMCID: PMC8780839 DOI: 10.3390/jcm11020417
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Category of three groups based on a quartile of variation of the Barthel index score: the 1st quartile (deterioration group, n = 25), the interquartile range (no remarkable change group, n = 55), and the 3rd quartile (good recovery group, n = 25).
Patient’s clinical and tumor characteristics.
| Overall ( | Deterioration Group ( | No Remarkable Change Group ( | Good Recovery Group ( | ||
|---|---|---|---|---|---|
| Age (years) | 67.0 ± 14.1 | 71.0 ± 12.2 | 66.7 ± 11.5 | 64.6 ± 11.5 | 0.24 |
| Men/Women ( | 59/46 | 11/14 | 31/24 | 16/9 | 0.34 |
| KPS at admission (median) | 57.9 ± 15.7 (60) | 61.2 ± 10.9 (60) | 59.6 ± 18.6 (60) | 50.4 ± 8.4 (50) | 0.01 |
| Extent of resection ( | 0.14 | ||||
| Gross and near total resection | 65 | 14 | 30 | 21 | |
| Partial resection | 23 | 6 | 15 | 2 | |
| Biopsy | 17 | 5 | 10 | 2 | |
| Treatments ( | 0.10 | ||||
| Surgery only | 5 | 1 | 4 | 0 | |
| Surgery + RT or TMZ or Bev | 10 | 4 | 6 | 0 | |
| Surgery + RT concomitant TMZ | 70 | 15 | 33 | 22 | |
| Surgery + RT concomitant TMZ + Bev | 20 | 5 | 12 | 3 | |
| Tumor location ( | |||||
| Frontal | 35 | 10 | 19 | 6 | 0.49 |
| Parietal | 23 | 7 | 8 | 8 | 0.15 |
| Temporal | 42 | 9 | 22 | 11 | 0.85 |
| Occipital | 7 | 3 | 3 | 1 | 0.46 |
| Others | 17 | 5 | 8 | 4 | 0.83 |
| Tumor hemisphere ( | 0.16 | ||||
| Right | 45 | 11 | 24 | 10 | |
| Left | 49 | 9 | 25 | 15 | |
| Bilateral | 11 | 5 | 6 | 0 | |
| Tumor size (mm) | 44.5 ± 13.8 | 48.0 ± 14.0 | 42.6 ± 13.1 | 50.0 ± 9.8 | 0.14 |
| Lengths of hospital stay (days) | 60.3 ± 16.4 | 59.2 ± 16.8 | 62.3 ± 18.7 | 57.0 ± 8.8 | 0.40 |
Values are mean ± SD. KPS, Karnofsky performance status; TMZ, temozolomide; RT, radiation therapy; Bev, Bevacizumab. † Some patients had a combined tumor location.
Figure 2Change in the Barthel index score at admission, at 7 days after surgery (after surgery), and at discharge. The median values are shown in the parenthesis.
Comparison of the deterioration and good recovery groups based on pre-, intra-, and post-operative factors.
| Deterioration Group | Good Recovery Group | Effect Size | ||
|---|---|---|---|---|
| Preoperative factors | ||||
| Length from initial symptoms to surgery (days) | 67.3 ± 45.8 | 37.8 ± 19.9 | 0.01 | 0.83 |
| Initial Symptoms ( | ||||
| Motor paralysis and muscle weakness | 5 | 13 | 0.03 | 0.34 |
| Cognitive dysfunction | 14 | 10 | 0.25 | 0.23 |
| Headache | 3 | 3 | 1.00 | 0.19 |
| Visual field defect | 3 | 1 | 0.60 | 0.00 |
| Dysphagia | 0 | 1 | 1.00 | 0.14 |
| Fatigue | 0 | 1 | 1.00 | 0.14 |
| Intraoperative factors | ||||
| Surgery time (minutes) | 555.0 ± 133.9 | 526.9 ± 127.7 | 0.47 | 0.22 |
| Bleeding volume (mL) | 692.0 ± 588.3 | 644.3 ± 529.3 | 0.78 | 0.09 |
| Transfusion volume (mL) | 117.9 ± 234.5 | 73.0 ± 210.5 | 0.51 | 0.20 |
| Infusion volume (mL) | 4086.0 ± 1144.5 | 4096.0 ±1108.5 | 0.98 | 0.01 |
| Fluid balance (mL) | 1317.0 ± 771.3 | 796.3 ± 929.9 | 0.05 | 0.60 |
| Postoperative factors # | ||||
| Fever ( | 6 | 4 | 0.73 | 0.10 |
| Infection ( | 4 | 2 | 0.67 | 0.12 |
| Pneumonia ( | 1 | 0 | 1.00 | 0.14 |
| Cerebral hemorrhage ( | 9 | 4 | 0.20 | 0.23 |
| Ischemic stroke ( | 5 | 1 | 0.10 | 0.24 |
| Motor paralysis (decreases BRS 2 stage or more) ( | 9 | 1 | <0.01 | 0.43 |
| Length from surgery to chemoradiotherapy (days) | 19.1 ± 8.8 | 17.0 ± 4.3 | 0.28 | 0.30 |
| RT and TMZ tolerance ( | ||||
| RT interruption or discontinuation | 3 | 1 | 0.11 | 0.29 |
| TMZ interruption or discontinuation | 8 | 3 | 0.14 | 0.28 |
Values are mean ± SD. † Patients with GBM have more than one type of symptoms. # Patients with GBM have more than one type of symptoms were collected at 7 days after surgery. BRS: Brunnstrom recovery stage; TMZ, temozolomide; RT, radiation therapy; GBM, glioblastoma multiforme.
Comparison of the deterioration and good recovery groups based on rehabilitation-related factors.
| Deterioration Group | Good Recovery Group | Effect Size | ||
|---|---|---|---|---|
| Length up to rehabilitation onset (days) | 2.6 ± 1.5 | 3.4 ± 2.3 | 0.17 | 0.39 |
| Length up to sitting training onset (days) | 4.8 ± 2.9 | 5.6 ± 5.1 | 0.54 | 0.19 |
| Length up to walking training onset (days) | 13.2 ± 16.7 | 8.4 ± 7.9 | 0.20 | 0.37 |
| Motor paralysis of (median of BRS) | ||||
| admission | 4.9 ± 1.2 (5) | 4.4 ± 1.4 (5) | 0.26 | 0.20 |
| after surgery | 3.7 ± 1.4 (4) | 4.3 ± 1.3 (5) | 0.19 | 0.22 |
| discharge | 4.0 ± 1.4 (4) | 5.5 ± 0.9 (6) | <0.01 | 0.55 |
| No motor paralysis ( | ||||
| admission | 6 | 9 | 0.53 | 0.11 |
| after surgery | 2 | 9 | 0.04 | 0.32 |
| discharge | 2 | 10 | 0.02 | 0.36 |
| Change from admission to discharge ( | ||||
| Deterioration of motor paralysis | 13 | 1 | <0.01 | 0.57 |
| Sever cognitive disorder or depression | 10 | 0 | <0.01 | 0.50 |
Values are mean ± SD. Motor paralysis showed the Brunnstrom recovery stage (BRS) of the lower limb.
Hematologic and non-hematologic toxicity during chemoradiotherapy in the deterioration and good recovery groups.
| Deterioration Group | Good Recovery Group | Effect Size | ||||||
|---|---|---|---|---|---|---|---|---|
| Grade 0 | Grade 1–2 | Grade 3–4 | Grade 0 | Grade 1–2 | Grade 3–4 | |||
| Hematologic toxicity | ||||||||
| Leukopenia | 10 (45) | 9 (41) | 3 (14) | 15 (60) | 9 (36) | 1 (4) | 0.26 | 0.29 |
| Neutropenia | 18 (78) | 2 (9) | 3 (13) | 16 (67) | 4 (17) | 4 (17) | 0.91 | 0.14 |
| Lymphocytopenia | 4 (17) | 11 (48) | 8 (35) | 7 (29) | 14 (58) | 3 (13) | 0.26 | 0.33 |
| Thrombocytopenia | 3 (13) | 20 (87) | 0 (0) | 5 (20) | 20 (80) | 0 (0) | 0.48 | 0.17 |
| Anemia | 3 (13) | 21 (87) | 0 (0) | 4 (16) | 19 (76) | 2 (8) | 0.18 | 0.35 |
| Non-hematologic toxicity | ||||||||
| Constipation | 9 (39) | 14 (61) | 0 (0) | 14 (56) | 10 (40) | 1 (4) | 0.36 | 0.26 |
| Fatigue | 6 (30) | 14 (70) | 0 (0) | 20 (80) | 5 (20) | 0 (0) | <0.01 | 0.50 |
| Fever | 11 (46) | 13 (54) | 0 (0) | 22 (88) | 3 (12) | 0 (0) | <0.01 | 0.45 |
† 1 patient missing for neutropenia and lymphocytopenia in the good recovery group and 1–5 patients missing for each toxicity in the deterioration group.
Figure 3Kaplan–Meier estimates for mobility the deterioration (dotted line) and good recovery groups (solid line).